Matches in SemOpenAlex for { <https://semopenalex.org/work/W2587303670> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2587303670 endingPage "4676" @default.
- W2587303670 startingPage "4676" @default.
- W2587303670 abstract "4676 Background: In the preliminary non-randomized study, combination therapy with natural IFN plus cimetidine showed high response rate in 15 out of 37 patients (41%) for advanced renal cell carcinoma. A prospective randomized multiinstitutional clinical trial to compare the effect of IFN alone to IFN + cimetidine in patients with advanced renal cell carcinoma with pulmonary metastasis was performed. Methods: Patients received IFN (5 megaunits) 5 times a week, or the IFN regimen plus daily oral cimetidine (800 mg). The primary end point was response rate, and time to progression (TTP). The secondary end point was overall survival. Results: Between April 1998 and March 2002, 71 patients from 32 institutions were randomly assigned to the two treatment groups. One patient in each group was found to be ineligible because they did not receive IFN at all. Two patients in IFN alone group stopped the treatment on day 9 and on day 10. Among 36 patients in IFN alone group, one CR, 4 PRs, 16 NCs, and 12 PDs were shown, with a response rate of 15.2%. Of 35 patients in IFN + cimetidine group, two CRs, 8 PRs, 13 NCs, and 11 PDs were observed, with a response rate of 29.4%. The difference was not significant (P=0.34). TTP ranged from 9 to 2307 days (median 179 days) in the IFN alone group, and from 31 to 3030 days (median 178 days) in IFN plus cimetidine group (p=0.86). The overall survival between the two groups was not significantly different either. The responses in pulmonary site were 1 CR, 3 PRs, 20 NCs, and 9 PDs in the IFN alone group, and 2 CRs, 7 PRs, 17 NCs, and 7 PDs in the combination therapy group (P=0.13). Conclusions: The combined treatment with IFN + cimetidine for advanced renal cell carcinoma could not have shown significant improvement in response rates or survival compared to IFN alone therapy. No significant financial relationships to disclose." @default.
- W2587303670 created "2017-02-17" @default.
- W2587303670 creator A5004687590 @default.
- W2587303670 creator A5014449911 @default.
- W2587303670 creator A5020661488 @default.
- W2587303670 creator A5029344563 @default.
- W2587303670 creator A5043058133 @default.
- W2587303670 creator A5056993350 @default.
- W2587303670 creator A5057940246 @default.
- W2587303670 creator A5072339165 @default.
- W2587303670 creator A5091294460 @default.
- W2587303670 date "2004-07-15" @default.
- W2587303670 modified "2023-10-16" @default.
- W2587303670 title "Prospective randomized trial of natural interferon-alpha (IFN) versus IFN + cimetidine in advanced renal cell carcinoma with pulmonary metastasis" @default.
- W2587303670 doi "https://doi.org/10.1200/jco.2004.22.90140.4676" @default.
- W2587303670 hasPublicationYear "2004" @default.
- W2587303670 type Work @default.
- W2587303670 sameAs 2587303670 @default.
- W2587303670 citedByCount "2" @default.
- W2587303670 countsByYear W25873036702017 @default.
- W2587303670 countsByYear W25873036702023 @default.
- W2587303670 crossrefType "journal-article" @default.
- W2587303670 hasAuthorship W2587303670A5004687590 @default.
- W2587303670 hasAuthorship W2587303670A5014449911 @default.
- W2587303670 hasAuthorship W2587303670A5020661488 @default.
- W2587303670 hasAuthorship W2587303670A5029344563 @default.
- W2587303670 hasAuthorship W2587303670A5043058133 @default.
- W2587303670 hasAuthorship W2587303670A5056993350 @default.
- W2587303670 hasAuthorship W2587303670A5057940246 @default.
- W2587303670 hasAuthorship W2587303670A5072339165 @default.
- W2587303670 hasAuthorship W2587303670A5091294460 @default.
- W2587303670 hasConcept C121608353 @default.
- W2587303670 hasConcept C126322002 @default.
- W2587303670 hasConcept C141071460 @default.
- W2587303670 hasConcept C168563851 @default.
- W2587303670 hasConcept C203014093 @default.
- W2587303670 hasConcept C203092338 @default.
- W2587303670 hasConcept C2776178377 @default.
- W2587303670 hasConcept C2777472916 @default.
- W2587303670 hasConcept C2779013556 @default.
- W2587303670 hasConcept C2780719153 @default.
- W2587303670 hasConcept C2781413609 @default.
- W2587303670 hasConcept C2909179924 @default.
- W2587303670 hasConcept C71924100 @default.
- W2587303670 hasConcept C90924648 @default.
- W2587303670 hasConceptScore W2587303670C121608353 @default.
- W2587303670 hasConceptScore W2587303670C126322002 @default.
- W2587303670 hasConceptScore W2587303670C141071460 @default.
- W2587303670 hasConceptScore W2587303670C168563851 @default.
- W2587303670 hasConceptScore W2587303670C203014093 @default.
- W2587303670 hasConceptScore W2587303670C203092338 @default.
- W2587303670 hasConceptScore W2587303670C2776178377 @default.
- W2587303670 hasConceptScore W2587303670C2777472916 @default.
- W2587303670 hasConceptScore W2587303670C2779013556 @default.
- W2587303670 hasConceptScore W2587303670C2780719153 @default.
- W2587303670 hasConceptScore W2587303670C2781413609 @default.
- W2587303670 hasConceptScore W2587303670C2909179924 @default.
- W2587303670 hasConceptScore W2587303670C71924100 @default.
- W2587303670 hasConceptScore W2587303670C90924648 @default.
- W2587303670 hasIssue "14_suppl" @default.
- W2587303670 hasLocation W25873036701 @default.
- W2587303670 hasOpenAccess W2587303670 @default.
- W2587303670 hasPrimaryLocation W25873036701 @default.
- W2587303670 hasRelatedWork W1212782987 @default.
- W2587303670 hasRelatedWork W1550484024 @default.
- W2587303670 hasRelatedWork W156517894 @default.
- W2587303670 hasRelatedWork W1854126421 @default.
- W2587303670 hasRelatedWork W1995490256 @default.
- W2587303670 hasRelatedWork W2038260901 @default.
- W2587303670 hasRelatedWork W2122157810 @default.
- W2587303670 hasRelatedWork W2226617841 @default.
- W2587303670 hasRelatedWork W2409509982 @default.
- W2587303670 hasRelatedWork W2414867669 @default.
- W2587303670 hasVolume "22" @default.
- W2587303670 isParatext "false" @default.
- W2587303670 isRetracted "false" @default.
- W2587303670 magId "2587303670" @default.
- W2587303670 workType "article" @default.